FULC Key Statistics, Chart & Performance
The current stock price of FULC is 10.94 USD. In the past month the price increased by 27.21%. In the past year, price increased by 184.16%.
FULC Latest News, Press Relases and Analysis
FULC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.91 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.53B | ||
| MRK | MERCK & CO. INC. | 11.9 | 260.19B | ||
| PFE | PFIZER INC | 8.04 | 146.35B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.16B | ||
| ZTS | ZOETIS INC | 20.22 | 56.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.74 | 23.10B | ||
| VTRS | VIATRIS INC | 4.59 | 12.31B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.24 | 11.56B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.23 | 8.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.64B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.80B |
Related stock screener links
About FULC
Company Profile
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 45 full-time employees. The company went IPO on 2019-07-18. The firm's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). The company uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The firm continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.
Company Info
FULCRUM THERAPEUTICS INC
26 Landsdowne Street
Cambridge MASSACHUSETTS 02139 US
CEO: Robert J. Gould
Employees: 45
Phone: 16176518851
FULCRUM THERAPEUTICS INC / FULC FAQ
What does FULC do?
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 45 full-time employees. The company went IPO on 2019-07-18. The firm's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). The company uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The firm continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.
Can you provide the latest stock price for FULCRUM THERAPEUTICS INC?
The current stock price of FULC is 10.94 USD. The price decreased by -3.36% in the last trading session.
What is the dividend status of FULCRUM THERAPEUTICS INC?
FULC does not pay a dividend.
What is the ChartMill rating of FULCRUM THERAPEUTICS INC stock?
FULC has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is FULCRUM THERAPEUTICS INC (FULC) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FULC.
When does FULCRUM THERAPEUTICS INC (FULC) report earnings?
FULCRUM THERAPEUTICS INC (FULC) will report earnings on 2026-02-23, after the market close.
FULC Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to FULC. When comparing the yearly performance of all stocks, FULC is one of the better performing stocks in the market, outperforming 97.81% of all stocks.
FULC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to FULC. While FULC has a great health rating, there are worries on its profitability.
FULC Financial Highlights
Over the last trailing twelve months FULC reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS decreased by -280.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.53% | ||
| ROE | -4.9% | ||
| Debt/Equity | 0 |
FULC Forecast & Estimates
13 analysts have analysed FULC and the average price target is 13.9 USD. This implies a price increase of 27.03% is expected in the next year compared to the current price of 10.94.
For the next year, analysts expect an EPS growth of -440.72% and a revenue growth -100% for FULC